Heidelberg Pharma AG
XETRA:HPHA
Heidelberg Pharma AG
Revenue
Heidelberg Pharma AG
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Heidelberg Pharma AG
XETRA:HPHA
|
Revenue
€9.9m
|
CAGR 3-Years
5%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
BioNTech SE
NASDAQ:BNTX
|
Revenue
€3.8B
|
CAGR 3-Years
99%
|
CAGR 5-Years
97%
|
CAGR 10-Years
N/A
|
|
MorphoSys AG
XETRA:MOR
|
Revenue
€238.3m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
26%
|
CAGR 10-Years
12%
|
|
Immatics NV
NASDAQ:IMTX
|
Revenue
€54m
|
CAGR 3-Years
20%
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
|
Biotest AG
XETRA:BIO
|
Revenue
€684.6m
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
3%
|
|
Formycon AG
XETRA:FYB
|
Revenue
€42.5m
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
See Also
What is Heidelberg Pharma AG's Revenue?
Revenue
9.9m
EUR
Based on the financial report for Nov 30, 2023, Heidelberg Pharma AG's Revenue amounts to 9.9m EUR.
What is Heidelberg Pharma AG's Revenue growth rate?
Revenue CAGR 5Y
22%
Over the last year, the Revenue growth was -47%. The average annual Revenue growth rates for Heidelberg Pharma AG have been 5% over the past three years , 22% over the past five years .